Medifast (MED) Liabilities and Shareholders Equity (2010 - 2026)

Medifast (MED) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $252.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 9.99% year-over-year to $252.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (down 9.7% YoY), and the FY2025 full-year result was $248.0 million, down 12.75% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $252.0 million, up from $248.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $421.4 million in Q1 2022 and bottomed at $248.0 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $302.8 million (2024), against an average of $303.8 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity increased 29.12%; it then dropped 23.69% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $316.2 million in 2022, then dropped by 1.99% to $309.9 million in 2023, then fell by 8.29% to $284.2 million in 2024, then declined by 12.75% to $248.0 million in 2025, then advanced by 1.64% to $252.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $252.0 million (Q1 2026), $248.0 million (Q4 2025), and $268.2 million (Q3 2025), per Business Quant data.

Peer Comparison